Drug Profile
Insulin glargine/insulin lispro - Adocia
Alternative Names: BC Combo; BC Combo THDB 0207; BioChaperone Combo; BioChaperone glargine/lispro; Insulin-lispro/insulin-glargineLatest Information Update: 05 Mar 2024
Price :
$50
*
At a glance
- Originator Adocia
- Class Antihyperglycaemics; Insulins; Pancreatic hormones
- Mechanism of Action Insulin receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Type 1 diabetes mellitus
- Phase I Type 2 diabetes mellitus
Most Recent Events
- 28 Feb 2024 Tonghua Dongbao plans a meeting with NMPA for preparing the next stages of development of Insulin glargine/insulin lispro - Adocia
- 28 Feb 2024 Tonghua Dongbao plans a phase III trial for Type 2 diabetes mellitus and Type 1 diabetes mellitus in China (SC) in 2024
- 23 Oct 2023 Adverse events and efficacy data from three phase-I trials in Type 1 diabetes mellitus and Type 2 diabetes mellitus released by Tonghua Dongbao